Navigation Links
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Date:8/27/2008

- Patients in the VELCADE, melphalan and prednisone arm demonstrated a significant survival benefit as well as a 30 percent complete response -

CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week's edition of the New England Journal of Medicine. The results showed a significant survival benefit and a 30 percent complete remission (CR) rate with VELCADE, melphalan and prednisone (VcMP) compared to 4 percent for melaphalan and prednisone (MP) alone in previously untreated multiple myeloma patients. Multiple myeloma is the second most common blood cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

"These data demonstrate that treatment with VELCADE plus melphalan and prednisone leads to a survival benefit and a high complete remission in previously untreated patients with multiple myeloma," said Professor Jesus San Miguel, M.D., Ph.D., Hematology Department Head, University Hospital of Salamanca and Principal Investigator of the trial. "The combination of VELCADE plus melphalan and prednisone is an important new option for these patients."

These data originally were presented at the 2007 American Society of Hematology (ASH) Annual Meeting. Based on these positive trial results, the U.S. Food and Drug Administration approved VELCADE for patients with previously untreated multiple myeloma on June 20, 2008. The Phase III VISTA trial was conducted by Millennium and its co-development partner Johnson & Johnson Pharmaceutical Research & Development, L.L.C. in 151 centers worldwide.

"We are proud to have these data published in such a highly esteemed journal," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "We're delighted that previously untreated multiple myeloma patient
'/>"/>

SOURCE Millennium
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
2. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
3. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
6. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
7. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
8. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/10/2014)... more likely to be diagnosed with more aggressive ... for shorter times than prostate cancer patients who ... , The negative outcomes may be the result ... mentally ill, depression,s impact on biological cancer processes, ... general health and disinterest in receiving more effective ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to talk ... their silent suffering if they are willing to ... Baylor University case study., After seven weeks of hypnotic ... flashes following prostate cancer surgery showed a drastic decrease ... improvement in sleep quality, according to the study., The ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
(Date:7/9/2014)... Cancer Center paint a relatively optimistic picture of women,s ... have spread to the chest wall or skin, but ... skin, regardless of size and whether they have involved ... and called "locally advanced" tumors, suggesting that they are ... survival. Locally advanced breast cancers of this and other ...
Breaking Medicine News(10 mins):Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Urban Aboriginal people face unique health challenges 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3
... , , , ... a contribution of up to $81.4 million to the Healthy Families Program ... children at risk of losing coverage due to the state,s fiscal crisis. ... be used to cover children ages 0-5 through June 2010. , ...
... studies find types of hormones used raise or lower ... The composition of a woman,s contraceptive pill influences her ... lung, European researchers say. , Scientists have long known ... and progestogen, increase the likelihood of deep vein thrombosis ...
... , , EDINA, Minn., Aug. 13 ... best interest of patients as a key focal point. We do ... and credit card fraud recently announced in the news. The MCA ... protect the public interest in this unfortunate situation. , ...
... , , , ... regarding changes to Mississippi Medicaid benefits for speech therapy services, The ... Mississippi Division of Medicaid on the new Medicaid claiming policy for ... for speech therapy services provided by school providers, which are in ...
... , , DEERFIELD, Ill., Aug. ... supplier of protective packaging products and specialty packaging solutions, today ... , For the second quarter of 2009, ... of 28.8% versus net sales of $275.2 million in the ...
... SANTA FE, N.M., Aug. 13 The New Mexico ... new alliance to assist school districts with Medicaid claiming. This program ... will be administered by Accelify. , , "We ... Executive Director. "NMSBA is focused on bringing value-added programs to New ...
Cached Medicine News:Health News:First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Program's Viability 2Health News:Some Birth Control Pills Safer Than Others 2Health News:Some Birth Control Pills Safer Than Others 3Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 2Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 3Health News:Pregis Announces Second Quarter 2009 Financial Results 2Health News:Pregis Announces Second Quarter 2009 Financial Results 3Health News:Pregis Announces Second Quarter 2009 Financial Results 4Health News:Pregis Announces Second Quarter 2009 Financial Results 5Health News:Pregis Announces Second Quarter 2009 Financial Results 6Health News:Pregis Announces Second Quarter 2009 Financial Results 7Health News:Pregis Announces Second Quarter 2009 Financial Results 8Health News:Pregis Announces Second Quarter 2009 Financial Results 9Health News:Pregis Announces Second Quarter 2009 Financial Results 10Health News:Pregis Announces Second Quarter 2009 Financial Results 11Health News:Pregis Announces Second Quarter 2009 Financial Results 12Health News:Pregis Announces Second Quarter 2009 Financial Results 13Health News:Pregis Announces Second Quarter 2009 Financial Results 14Health News:Pregis Announces Second Quarter 2009 Financial Results 15Health News:New Mexico School Boards Association and Accelify Announce Alliance to Assist New Mexico Schools 2
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
... Medtronic presents the Streamline family of temporary ... taken the gold standard in temporary pacing ... make them easy to use and less ... 6491 Unipolar Pediatric Temporary Pacing Lead is ...
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Medicine Products: